Abstract
Aims: Flavonoids naturally exist in plants as secondary metabolites. In this study, the aim is to determine and compare the theoretical and in vivo chemical activities of 7,8- dihydroxyflavone (7,8-DHF) and 4'dimethylamino-7,8-dihydroxyflavone (4’-DMA-7,8-DHF), tyrosine receptor kinase B (TrkB) receptor agonist flavonoid molecules with reported potent neuroprotective effects.
Methods: The density functional theory (DFT) (RB3LYP) method was used for the theoretical chemical analysis. For the in vivo studies, 6-month-old Wistar rats were used in two groups (n=8). 7,8-DHF and 4’-DMA-7,8-DHF (5 mg/kg) were administered intraperitoneally (ip) to each group. Then, plasma samples were collected by carotid catheterization, and brain samples by the microdialysis technique were collected simultaneously for 12 h from awake rats. The level of 7,8-DHF and 4’-DMA-7,8-DHF in blood and brain samples were analyzed and their pharmacokinetics were determined.
Results: Theoretical calculations show that 7,8-DHF is slightly more stable than 4’-DMA-7,8- DHF. The in vivo pharmacokinetic results show that the maximum concentration of 7,8-DHF was about 48 ng/mL, whereas it was only 8 ng/mL for 4’-DMA-7,8-DHF.
Conclusion: Our results suggest that the 4'-DMA-7,8-DHF is more unstable and is more prone to binding to TrkB than 7,8-DHF. On the other hand, the in vivo pharmacokinetic results show that 7,8-DHF is more stable than 4’-DMA-7,8-DHF when it is applied systemically at therapeutic concentrations.
Graphical Abstract
[http://dx.doi.org/10.1146/annurev.neuro.24.1.677] [PMID: 11520916]
[http://dx.doi.org/10.1038/mp.2009.67] [PMID: 19621014]
[http://dx.doi.org/10.3389/fnmol.2014.00039] [PMID: 24860421]
[http://dx.doi.org/10.1016/j.cub.2005.10.045] [PMID: 16332537]
[http://dx.doi.org/10.1038/s41598-020-65531-x]
[http://dx.doi.org/10.1016/0955-0674(95)80022-0] [PMID: 7612265]
[http://dx.doi.org/10.1016/j.psyneuen.2019.104473] [PMID: 31655452]
[http://dx.doi.org/10.1016/j.cell.2021.01.034] [PMID: 33606976]
[http://dx.doi.org/10.2147/IJN.S77480] [PMID: 25995632]
[http://dx.doi.org/10.1016/j.pharmthera.2007.03.005] [PMID: 17599430]
[http://dx.doi.org/10.1016/j.neuint.2013.10.018] [PMID: 24220540]
[http://dx.doi.org/10.1038/npp.2013.243] [PMID: 24022672]
[http://dx.doi.org/10.1016/j.ejphar.2018.02.045] [PMID: 29510124]
[http://dx.doi.org/10.1371/journal.pone.0091453] [PMID: 24614170]
[http://dx.doi.org/10.1016/j.neulet.2016.03.042] [PMID: 27019033]
[http://dx.doi.org/10.1016/j.neuroscience.2014.12.080] [PMID: 25655214]
[http://dx.doi.org/10.1016/j.neulet.2014.02.058] [PMID: 24637017]
[http://dx.doi.org/10.3892/or.2014.3632] [PMID: 25434704]
[http://dx.doi.org/10.3892/or.2016.4825] [PMID: 27220989]
[http://dx.doi.org/10.2174/18715273113129990061] [PMID: 23469848]
[http://dx.doi.org/10.3892/ijmm.2015.2256] [PMID: 26096841]
[http://dx.doi.org/10.1073/pnas.1718683115] [PMID: 29295929]
[http://dx.doi.org/10.1212/WNL.62.6_suppl_4.S8] [PMID: 15037665]
[http://dx.doi.org/10.1021/jm101206p] [PMID: 21073191]
[http://dx.doi.org/10.5897/IJMMS2014.1030]
[http://dx.doi.org/10.1002/jbt.22215] [PMID: 30194790]
[PMID: 29567235]
[http://dx.doi.org/10.33435/tcandtc.813939]
[http://dx.doi.org/10.1080/01635581.2021.1895233] [PMID: 33724114]
[http://dx.doi.org/10.1159/000346920] [PMID: 23445871]
[http://dx.doi.org/10.1124/dmd.30.2.199] [PMID: 11792691]